Mother's milk provides multiple benefits to the offspring. However, xenobiotics transferred into breast milk may pose a risk to the nursing infant. The breast cancer resistance protein (BCRP) actively transports xenobiotics into breast milk. BCRP also transports nutrients, like riboflavin, and together with recently identified riboflavin transporters (RFT), may provide a mechanism for riboflavin secretion into breast milk. Expression of RFT in the mammary gland remained unknown. Our objective was to characterize Bcrp and Rft mRNA expression in the mammary gland of FVB/N mice, and investigate a strategy to decrease excretion of BCRP-transported xenobiotics into the milk using riboflavin intervention. Rft and Bcrp mRNA were upregulated in the mammary gland of lactating mice. An intravenous riboflavin administration significantly reduced the levels of BCRP-transported cimetidine in milk. This study demonstrates the use of riboflavin to exploit the function of mammary BCRP in order to reduce xenobiotic secretion into breast milk.

The present study focuses on adaptive metabolic steps adopted by neutrophils during inflammation, particularly during their recruitment into the cystic fibrosis (CF) airways. In CF, we previously described that airway neutrophils are alive and undergo reprogramming, featuring notably the activation of the anabolic mTOR pathway. The present work is based on specific properties of soluble ligands derived from the receptor-binding domains (RBD) of retroviral glycoprotein envelopes, which can be used for the detection of metabolite transporters at the cell surface. First, we validated the use of this new set of markers for the identification and characterization of the metabolic phenotype of CF leukocytes obtained from distinct compartments (blood and sputum). Second, by studying the metabolite transporter expression on blood neutrophils from CF or rheumatoid arthritis patients and control subjects, we distinguished metabolic phenotypes characteristic of specific inflammatory states. Then, we compared metabolite transporter expression between CF blood and airway neutrophils and showed that neutrophils undergo significant metabolic adaptation upon recruitment into the lungs. Finally, we demonstrated that CF airway neutrophils display significant transcriptional modulation and that despite their metabolic reprogramming, they remain functionally competent, thus adding an additional angle of approach to neutrophil studies with regard to inflammation, notably during CF airway disease.

Resistance to chemotherapy is partly due to efflux pumps expressed in the plasma membrane which prevents the accumulation of anticancer, antiviral, antifungal and antibacterial drugs in target cells. Three human ABC transporters are particularly involved in MDR phenotype: P-gp/ABCB1, MRP1/ABCC1 and BCRP/ABCG2. Among the different approaches used to overcome the resistance linked to these transporters, the development of non-substrate drugs MDR-ABC transporters has been described. Here, new class of HIV-1 protease inhibitors not recognized by P-gp/BCRP were identified, promising to be attractive candidates to HAART therapy. Since the determination of the X-ray structures in different conformations is a key point to understand how MDR-ABC transporters translocate drugs across the plasma membrane, the crystal structures of three inward-facing conformations of mouse P-gp were resolved. One structure has a camel nanobody bound to the C-terminal side of the first nucleotide-binding domain, revealing a unique epitope on P-gp and freezing a new open-inward conformation. Finally, the enzymatic characterization of two inhibitors co-crystallized with the mouse P-gp has allowed to localize two main binding sites by which drugs efflux occurs. These results bring new findings of the drug-efflux mechanism and offer the possibility to target more precisely those sites to develop modulators of this pump

Adenosine is an essential purine nucleoside of particular importance within heart and brain. The widespread and diverse actions of adenosine, driven by activation of cell surface receptors, include regulation of sleep/arousal and neuroprotective properties. The mechanisms involved in regulating adenosine concentrations remain poorly understood but are critical to signaling pathways as they determine the availability of adenosine at corresponding receptors within the extracellular space. The equilibrative nucleoside transporter (ENT) family, bi-directional, Na+-independent nucleoside transporters, are key components in both the release and uptake of adenosine. This study has been conducted to investigate ENT3, a novel member of the ENT family. Our work has demonstrated ENT3 to be expressed throughout brain, located in cortex, cerebellum, striatum and hippocampus, at similar levels. Neurons and astrocytes, but not microglia, showed intracellular ENT3 localisation. This was confirmed by differential centrifugation, of cortex and cerebellum, which suggests ENT3 to be found within the cytoplasm.

Thesis (Ph. D.)--University of Washington, 1998. / Vita. Includes bibliographical references (leaves [100]-113).

Le catabolisme exacerbé du glucose et de la glutamine est actuellement reconnu comme une caractéristique des cellules cancéreuses, qui leur procure un avantage prolifératif via la production et l’accumulation de plusieurs métabolites au niveau du microenvironnement. Parmi ces métabolites, l’acide lactique représente une molécule de signalisation clé, favorisant la migration et les métastases. Mon projet de thèse s’inscrit dans le contexte d’une étude du métabolisme glycolytique associé aux cellules tumorales à division rapide. Durant ce projet, nous nous sommes intéressés à la caractérisation génétique et fonctionnelle des transporteurs MCT (MonoCarboxylate Transporters) 1 et 4, qui sont des symporteurs H+/lactate dont l’expression membranaire et la fonctionnalité requièrent la liaison avec une protéine chaperonne : CD147/BASIGINE (BSG). Afin de mieux explorer la physiologie des complexes MCT/BSG, et valider le ciblage de l’export d’acide lactique comme une nouvelle approche anti-cancer, nous avons développé une stratégie visant à invalider le gène BSG et/ou MCT4, en utilisant la technologie des Zinc Finger Nucleases (ZFN), dans des lignées cellulaires cancéreuses humaines de côlon, poumon et glioblastome. D’abord, nous avons démontré, que l’effet pro-tumoral majeur de BSG est lié à son action directe sur la stabilisation des MCTs au niveau des tumeurs glycolytiques et non pas à la production des metalloprotéases. Ensuite, nous avons démontré pour la première fois que l’inhibition concomitante de MCT1 et MCT4 est nécessaire pour induire une baisse significative de la tumorigénécité in vivo. / Enhanced glucose and glutamine catabolism has become a recognized feature of cancer cells, leading to accumulation of metabolites in the tumour microenvironment, which offers growth advantages to tumours. Among these metabolites is emerging as a key signalling molecule that plays a pivotal role in cancer cell migration and metastasis. In this thesis, we focused on the genetic and functional characterization of monocarboxylate transporters (MCT) 1 and 4, which are H+/lactate symporters that require an interaction with an ancillary protein, CD147/BASIGIN (BSG), for their plasma membrane expression and function. To further explore the physiology of MCT/BSG complexes and validate the blockade of lactic acid export as an anti-cancer strategy, we designed experiments using Zinc Finger Nuclease mediated BSG and/or MCT4 gene knockouts in human colon adenocarcinoma, lung carcinoma and glioblastoma cell lines. First of all, we demonstrated that the major protumoural action of BSG is to control the energetics of glycolytic tumours via MCT1/4 activity and not to produce matrix metalloproteases. Second, we showed for the first time that combined inhibition of both MCT1 and MCT4 transporters is required to achieve a significant reduction in the tumour growth in vivo. Moreover, our findings reported that disruption of the BSG gene dramatically reduced the plasma membrane expression and lactate transport activity of both MCT1 and MCT4, leading to increased accumulation of intracellular pools of lactic and pyruvic acids, decreased intracellular pH and reduced rate of glycolysis.

A levedura Saccharomyces cerevisiae, amplamente utilizada na conversão de glicose e frutose a etanol, não é capaz de fermentar a xilose presente na biomassa lignocelulósica de resíduos agroindustriais. Apesar da introdução da via metabólica dessa pentose em linhagens de S. cerevisiae, a fermentação da xilose simultaneamente com outros açúcares ainda é pouco eficiente. A proposta deste trabalho foi aumentar a eficiência do consumo da xilose por linhagens de S. cerevisiae introduzindo genes de transportadores exógenos identificados em leveduras selvagens que naturalmente fermentam pentoses. A via do metabolismo da xilose foi integrada no genoma de uma linhagem industrial brasileira de S. cerevisiae usada na produção de etanol. A partir desta, linhagens isogênicas foram criadas e mostraram ser mais eficientes no metabolismo da xilose em meio sintético e capazes de co-fermentar glicose e xilose na presença de altas concentrações de inibidores resultantes da hidrólise da biomassa lignocelulósica. Os tranportadores identificados foram testados nas linhagens industriais geneticamente modificadas criadas neste estudo e em linhagens laboratoriais. Não foi possível confirmar a eficiência dos transportadores nas linhagens, embora os resultados mostraram diferenças nas curvas de crescimento das linhagens industriais expressando os transportadores. Este trabalho foi o início de um estudo dos fatores envolvidos no metabolismo da xilose e servirá como base para que futuros trabalhos sejam realizados na obtenção de uma linhagem mais eficiente para produção de etanol de segunda geração. / The yeast Saccharomyces cerevisiae, which efficiently ferments glucose and fructose to ethanol, is unable to ferment xylose present in lignocellulosic biomass of agroindustrial residues. Although the introduction of xylose metabolic pathways in S. cerevisiae strains has been described in the literature, the simultaneous fermentation of xylose and glucose in these modified strains is still very inefficient. The aim of this study was to increase the xylose consumption efficiency of S. cerevisiae by introduction of exogenous genes identified in wild yeast that naturally ferment pentose. The xylose metabolism pathway was integrated into the genome of a Brazilian industrial strain of S. cerevisiae used for the production of ethanol, which was then used to obtain isogenic modified strains. The isogenic strains showed to be more effective in xylose metabolism in synthetic medium and able to co-ferment glucose and xylose in the presence of high concentrations of inhibitors resulting hydrolysis of lignocellulosic biomass. The transporters identified were inserted into genetically modified industrial strains of S. cerevisiae created in this study and also in laboratory strains. It was not possible to confirm the transporters efficiency in laboratory strains but the results showed differences in the growth curves of the industrial strains expressing the transporters. This work was the beginning of a study of the factors involved in xylose metabolism and it will help to prepare future work to obtain an efficient strain for lignocellulosic ethanol production.

The kidneys have a significant role in drug elimination through both metabolic and excretory routes. Despite a recent paradigm shift towards systems pharmacology approaches, prediction of renal drug disposition using 'bottom-up' and mechanistic modelling approaches remains underdeveloped. Lack of 'gold-standard' in vitro assays and corresponding in vitro-in vivo extrapolation (IVIVE) approaches for prediction of renal metabolic (CLR,met) and excretory (CLR) clearances contribute to this. A comprehensive literature analysis of quantitative physiological data to inform renal IVIVE scaling factors and systems parameters relevant for physiologically based pharmacokinetic (PBPK) kidney models was initially performed to identify existing knowledge gaps. Following this, microsomal protein content in dog kidney cortex (MPPGK) and liver (MPPGL) were measured in 17 samples from the same animal. Mean dog MPPGK (44.0 mg/ g kidney) and MPPGL (63.6 mg/ g liver) obtained using glucose-6-phosphatase activity as the microsomal protein marker where systematically higher than when CYP content was used as the marker (33.9 mg/ g kidney and 41.1 mg/ g liver respectively). Dog MPPGK was lower than MPPGL, with no direct correlation between the organs. In addition to dog, MPPGK and cytosolic protein per gram kidney (CPPGK) were obtained from 31 human samples, which represent the largest dataset currently available. Mean human MPPGK (25.7 mg/ g kidney) and CPPGK (52.7 mg/ g kidney), were measured using glucose-6-phosphatase and glutathione-S-transferase activities as recovery markers, respectively. Activity of prepared kidney microsomes was assessed using mycophenolic acid glucuronidation as a marker. Novel scaling factor of 25.7 mg/ g kidney was applied for IVIVE of mycophenolic acid microsomal glucuronidation data, resulting in a 2-fold increase in scaled intrinsic clearance compared with data scaled by the commonly used literature MPPGK value (12.8 mg/ g kidney). In addition to the microsomal scaling factor, several elements of a modified stereology method were developed for quantifying human proximal tubule cellularity. The methods included implementation of a systematic uniform random sampling protocol and investigation of tinctorial and immunohistochemistry based staining approaches that could be used identify and count proximal tubule cells in histology sections. A range of mechanistic models for prediction of CLR via either tubular reabsorption or active secretion were developed. A novel 5-compartment model for prediction of tubular reabsorption and CLR from Caco-2 apparent permeability data was developed. This model accounted for relevant physiological complexities of the kidney, such as regional differences in tubular filtrate flow rates and tubular surface area, including consideration of the impact of microvilli. The model predicted the CLR of 45 drugs with overall good accuracy (geometric mean fold error of 1.96), although a systematic under-prediction was noted for basic drugs. The novel 5-compartment model represents an important addition to the IVIVE toolbox for physiologically-based prediction of renal tubular reabsorption and CLR and can be implemented in the more complex mechanistic kidney models, as shown in the case of prediction of urine flow dependent CLR of theophylline and caffeine. Final part of the Thesis focused on the refinement of digoxin PBPK kidney model and its ability to predict effect of aging and renal impairment on digoxin CLR. The analysis has identified that reducing either the proximal tubule cellularity or OATP4C1 abundance parameters in the mechanistic model recovers well observed reduced tubular secretion and CLR of digoxin in renal impairment populations whereas no effect of modification of P-gp abundance was observed. Conversely, reducing the proximal tubule cellularity, OATP4C1 abundance or P-gp abundance parameters in the model resulted in negligible change, decreased or increased accumulation of digoxin in proximal tubule cells, respectively. In conclusion, the current study provides to date the most comprehensive kidney microsomal and cytosolic metabolic scaling factors, together with revised database on renal physiological data necessary for quantitative prediction of renal drug disposition. Mechanistic modelling work shown here has highlighted a need for physiological data from different population groups to inform kidney model parameters, in order to improve the scope and utility of such models within the systems pharmacology paradigm.

A levedura Saccharomyces cerevisiae, amplamente utilizada na conversão de glicose e frutose a etanol, não é capaz de fermentar a xilose presente na biomassa lignocelulósica de resíduos agroindustriais. Apesar da introdução da via metabólica dessa pentose em linhagens de S. cerevisiae, a fermentação da xilose simultaneamente com outros açúcares ainda é pouco eficiente. A proposta deste trabalho foi aumentar a eficiência do consumo da xilose por linhagens de S. cerevisiae introduzindo genes de transportadores exógenos identificados em leveduras selvagens que naturalmente fermentam pentoses. A via do metabolismo da xilose foi integrada no genoma de uma linhagem industrial brasileira de S. cerevisiae usada na produção de etanol. A partir desta, linhagens isogênicas foram criadas e mostraram ser mais eficientes no metabolismo da xilose em meio sintético e capazes de co-fermentar glicose e xilose na presença de altas concentrações de inibidores resultantes da hidrólise da biomassa lignocelulósica. Os tranportadores identificados foram testados nas linhagens industriais geneticamente modificadas criadas neste estudo e em linhagens laboratoriais. Não foi possível confirmar a eficiência dos transportadores nas linhagens, embora os resultados mostraram diferenças nas curvas de crescimento das linhagens industriais expressando os transportadores. Este trabalho foi o início de um estudo dos fatores envolvidos no metabolismo da xilose e servirá como base para que futuros trabalhos sejam realizados na obtenção de uma linhagem mais eficiente para produção de etanol de segunda geração. / The yeast Saccharomyces cerevisiae, which efficiently ferments glucose and fructose to ethanol, is unable to ferment xylose present in lignocellulosic biomass of agroindustrial residues. Although the introduction of xylose metabolic pathways in S. cerevisiae strains has been described in the literature, the simultaneous fermentation of xylose and glucose in these modified strains is still very inefficient. The aim of this study was to increase the xylose consumption efficiency of S. cerevisiae by introduction of exogenous genes identified in wild yeast that naturally ferment pentose. The xylose metabolism pathway was integrated into the genome of a Brazilian industrial strain of S. cerevisiae used for the production of ethanol, which was then used to obtain isogenic modified strains. The isogenic strains showed to be more effective in xylose metabolism in synthetic medium and able to co-ferment glucose and xylose in the presence of high concentrations of inhibitors resulting hydrolysis of lignocellulosic biomass. The transporters identified were inserted into genetically modified industrial strains of S. cerevisiae created in this study and also in laboratory strains. It was not possible to confirm the transporters efficiency in laboratory strains but the results showed differences in the growth curves of the industrial strains expressing the transporters. This work was the beginning of a study of the factors involved in xylose metabolism and it will help to prepare future work to obtain an efficient strain for lignocellulosic ethanol production.

L'hydrolyse de l'ATP en ADP constitue la principale source d'énergie de la cellule. Le transport de ce nucléotide depuis son lieu de synthèse vers le cytosol est essentiel pour la plupart des réactions métaboliques et nécessite un passage à travers les membranes. Ainsi, un grand nombre de transporteurs d'ATP/ADP sont présents dans les différents organites tels que les mitochondries, les chloroplastes, et autres types de plastides mais aussi chez les bactéries pathogènes (Rickettsia prowazekii, Protoclamydiae amoebophila) (Trentmann et al, 2007).L'équipe s'intéresse principalement à 2 types de transporteurs d'ADP et d'ATP, la famille des transporteurs mitochondriaux (MCF) et la famille des NTT (plastes et bactéries). Malgré des fonctions similaires, ces 2 familles de transporteurs possèdent des propriétés biochimiques et structurales différentes. De nos jours, il n'existe aucune information structurale disponible sur la famille des NTTs. La détermination de cette structure pourrait permettre de comprendre le mécanisme de transport de ces transporteurs mais plus généralement comprendre le transport de l'ATP et ADP dans les cellules.Une étude a été initiée sur la structure et la fonction de la famille des NTT plus particulièrement des transporteurs chloroplastiques d'Arabidopsis thaliana mais aussi des transporteurs bactériens. Toutefois, ma thèse concerne principalement les transporteurs chloroplastiques NTT1 et NTT2. Ces 2 isoformes sont localisées dans la membrane interne des chloroplastes et permettent de pourvoir le stroma en ATP lorsque la photosynthèse ne peut pas avoir lieu par manque de lumière.Nous avons déterminé et optimisé les conditions de surexpression des 2 isoformes dans un système hétérologue puis de purification en détergent). Nous avons mis au point des méthodes permettant de caractériser le transporteur en solution et de mesurer son activité dans le but d'aboutir à une étude structurale. Des pistes de cristallisation ont également étaient obtenues. / ATP is the main energy currency in the cell and its transport across membranes is essential for most of the metabolic reactions. A large number of ATP/ADP transporters are present in the different cell organelles such as mitochondria, chloroplasts, other types of plastids and some are also found in bacteria (Rickettsia prowazekii, Protoclamydiae amoebophila) (Trentmann et al, 2007). The team is mainly interested in two distinct transporters families, the mitochondrial carrier family (MCF) and the NTT family. Despite similar function, mitochondrial ADP/ATP transporters (Pebay-Peyroula et al, 2003) and NTT proteins exhibit different structural and biochemical properties. To date no structural information is available on the NTT family. The determination of a structure would help for understanding the transport mechanism of these carriers and more generally the different mechanisms of the transport of ADP and ATP within the cell.We initiated a structure-function study on the NTT family focusing on chloroplast transporters from Arabidopsis thaliana and also from bacteria. My thesis is focused on chloroplast NTT1 and NTT2. These isoforms are localized in the inner membrane of chloroplast. They transport ATP inside the chloroplast in order to supply the different reactions occurring in the stroma when the photosynthesis does not occur.We have determined and optimized conditions to overexpress these 2 isoforms in heterologous systems and to purify the protein in detergents. We have also set up tools to characterize the carrier in solution and to measure its transport activity opening the way to functional and structural studies. We obtained promising crystallization hits.